Pharma Industry Faces Trust Gap with Agentic AI Adoption, Reports Suggest
The pharmaceutical industry is approaching agentic AI with significant caution, with reports indicating only 50% of professionals trust AI for consistent accuracy. Trust levels drop further for critical decisions involving drug pipelines and intellectual property protection, creating adoption challenges.
Pharma’s Cautious Approach to Agentic AI Implementation
The pharmaceutical industry is developing a divided market regarding artificial intelligence adoption, with sources indicating that rapid adopters with substantial budgets are moving toward standardized agentic systems while more cautious organizations focus on targeted pilot programs. According to reports, companies pursuing specific use cases with clear return on investment pathways represent the more measured approach to integration.